Uliledlimab is an antibody designed to target CD73. The development pause will also allow I-Mab to allow data from an ongoing ...

By adapting artificial intelligence models known as large language models, researchers have made great progress in their ...

Invenra has launched its Rapid Antibody Discovery Service, designed to simplify and de-risk the preclinical development of ...

Transaction Expands Climb Bio’s Pipeline of B-cell Targeted Therapeutics to Address Immune-mediated DiseasesNew Program is a ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Oxford, UK and San Jose, California, 9 January 2024 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a ...

Thanks to an innovative method of super-resolution microscopy, researchers observed with molecular resolution in 3D how therapeutic antibodies attack and alter B cells, thereby inducing their ...

Scientists from Duke-NUS Medical School and the Singapore General Hospital have discovered that T cells—white blood cells ...

Achievement strengthens iBio’s partnered cardiometabolic and obesity program while showcasing its proprietary AI-driven drug ...

Boehringer Ingelheim has acquired a licence for the development of antibody-based cancer treatments from Oxford ...

A panelist discusses how loncastuximab tesirine, an antibody-drug conjugate targeting CD19, shows promise in combination with ...